Abstract
Alzheimers disease is an age-related neurodegenerative disease which causes global loss of cognitive function. Drug treatment for Alzheimers disease has been limited to agents that ameliorate behavioral symptoms but these agents are without effect on disease progression. Rational drug design for the treatment of Alzheimers disease now seems possible. As a result of major advances in medical research in this area, knowledge of the etiology of Alzheimers disease is rapidly being understood. This information has uncovered relevant and novel targets for treatment. At the center of the etiological progression of this disease is β-amyloid. A substantial body of evidence strongly suggests that this small protein is critical to the development of Alzheimers disease. The β-amyloid protein is generated by two different proteolytic cleavages. Recently, the proteases responsible for producing the β-amyloid protein have been identified. The proteases represent viable targets for therapeutic intervention against Alzheimers disease. In this review, we describe the biological characteristics of the β-amyloid-forming proteases in the context of pharmaceutical development.
Keywords: Amyloid, Proteases, Alzheimers Disease
Current Pharmaceutical Design
Title: Amyloid Forming Proteases: Therapeutic Targets for Alzheimers Disease
Volume: 8 Issue: 28
Author(s): Frauke Schimmoller, Jeffrey N. Higaki and Barbara Cordell
Affiliation:
Keywords: Amyloid, Proteases, Alzheimers Disease
Abstract: Alzheimers disease is an age-related neurodegenerative disease which causes global loss of cognitive function. Drug treatment for Alzheimers disease has been limited to agents that ameliorate behavioral symptoms but these agents are without effect on disease progression. Rational drug design for the treatment of Alzheimers disease now seems possible. As a result of major advances in medical research in this area, knowledge of the etiology of Alzheimers disease is rapidly being understood. This information has uncovered relevant and novel targets for treatment. At the center of the etiological progression of this disease is β-amyloid. A substantial body of evidence strongly suggests that this small protein is critical to the development of Alzheimers disease. The β-amyloid protein is generated by two different proteolytic cleavages. Recently, the proteases responsible for producing the β-amyloid protein have been identified. The proteases represent viable targets for therapeutic intervention against Alzheimers disease. In this review, we describe the biological characteristics of the β-amyloid-forming proteases in the context of pharmaceutical development.
Export Options
About this article
Cite this article as:
Schimmoller Frauke, Higaki N. Jeffrey and Cordell Barbara, Amyloid Forming Proteases: Therapeutic Targets for Alzheimers Disease, Current Pharmaceutical Design 2002; 8 (28) . https://dx.doi.org/10.2174/1381612023392658
DOI https://dx.doi.org/10.2174/1381612023392658 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Myocardial Infarction. Pathological Relevance and Relationship with Coronary Risk Factors
Current Pharmaceutical Design Glycation of Human Serum Albumin in Diabetes: Impacts on the Structure and Function
Current Medicinal Chemistry Global Life-Long Health Benefits of Repression of Hypothalamic NPY System by Central Leptin Gene Therapy
Current Topics in Medicinal Chemistry Semicarbazide-Sensitive Amine Oxidase: Current Status and Perspectives
Current Medicinal Chemistry Anti-Inflammatory Agents in Ageing and Age-Associated Diseases
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Periodontal Regenerative Materials and Their Applications: Goodness of Fit?
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Tetrahydrobiopterin Biosynthesis, Utilization and Pharmacological Effects
Current Drug Metabolism A Systematic Review on Organophosphate Pesticide and Type II Diabetes Mellitus
Current Diabetes Reviews Impact of Ivabradine on Health-Related Quality of Life of Patients with Ischaemic Chronic Heart Failure
Current Vascular Pharmacology Peptide and Non-peptide Antagonists Targeting Endothelin Receptors in Physiology and Pathology
Current Pharmaceutical Design Dietary Habits of Mongolian People, and Their Influence on Lifestyle-Related Diseases and Early Aging
Current Aging Science Integrated Protocol to Design Potential Inhibitors of Dipeptidyl Peptidase- 4 (DPP-4)
Current Topics in Medicinal Chemistry Recent Advances in Synthetic Chemistry of Diabetic Research
Mini-Reviews in Medicinal Chemistry MicroRNA-mediated Regulation of Angiogenesis
Current Angiogenesis (Discontinued) Natriuretic Peptide Family: New Aspects
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Meet Our Editorial Board Member
Current Women`s Health Reviews Treatment of IgG4-Related Disease
Current Immunology Reviews (Discontinued) Targeting Farnesoid-X-Receptor: From Medicinal Chemistry to Disease Treatment
Current Medicinal Chemistry Domperidone and Long QT Syndrome
Current Drug Safety The Wnt/β-catenin Signalling Pathway Inhibitor Sclerostin is a Biomarker for Early Atherosclerosis in Obesity
Current Neurovascular Research